Skip to main content
Fig. 2 | Critical Care

Fig. 2

From: Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study

Fig. 2

CAPA incidence according to antifungal prophylaxis. 30-day CAPA incidence in patients without (red curve) and with (black curve) mould active antifungal prophylaxis. A competing risk analysis was performed as death is a competing risk for development of CAPA. Panel A denotes the unadjusted analysis (17.5 vs 1.4%, p = 0.002). Panel B denoted the IPTW weighted (adjusted) analysis (15.8 vs 1.1%, p = 0.002). Abbreviation: AF antifungal prophylaxis; CAPA COVID-19-associated pulmonary aspergillosis; ICU intensive care unit

Back to article page

Critical Care

ISSN: 1364-8535